Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa trial of Longkoma quadrivalent recombinant norovirus vaccine in participants aged 6 weeks and older
ChiCTR2400089762Phase 2Completed
- Sponsor
- Guangxi Zhuang Autonomous Region Centre for Disease Control and Prevention
- Start
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tetravalent recombinant norovirus vaccine in Noroviral gastroenteritis (17 arms), sponsored by Guangxi Zhuang Autonomous Region Centre for Disease Control and Prevention. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 4 more. Started Sep 2024; status: completed.
02
Drugs
tetravalent recombinant norovirus vaccine
03
Conditions
Noroviral gastroenteritis
Beyond the preview
Go deeper on ChiCTR2400089762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089762.